ACH-3102 Receives Fast Track Designation From The FDA For The Treatment Of Chronic Hepatitis C (ACHN)

ACH-3102 Receives Fast Track Designation From The FDA For The Treatment Of Chronic Hepatitis C (ACHN)

Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. Achillion's proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease including HCV and resistant bacterial infections.

GP Strategies to Attend 13th Annual B. Riley & Co. Investor Conference - $GPX

GP Strategies to Attend 13th Annual B. Riley & Co. Investor Conference - $GPX

Global performance improvement solutions provider GP Strategies Corporation (NYSE: GPX) announced that Scott Greenberg, Chief Executive Officer, and Sharon Esposito-Mayer, Chief Financial Officer, are scheduled to present at the 13th Annual B. Riley & Co. Investor Conference on Tuesday, May 22, 2012 at 2:30 pm PDT. The conference will be held at the Loews Santa Monica Beach Hotel in Santa Monica, California.  The presentation slides will be available on the Investors section of the company's website at http://investors.gpstrategies.com/events.aspx.

Rodman & Renshaw On Amylin: Bydureon Posts Flat NRx Market Share, While GLP-1 TRx Grow Over 5% Sequentially (AMLN)

Rodman & Renshaw On Amylin: Bydureon Posts Flat NRx Market Share, While GLP-1 TRx Grow Over 5% Sequentially (AMLN)

Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. The company is particularly focused on the therapeutic potential of new peptide hormone drug candidates and the creation of novel and groundbreaking therapies for the treatment of diabetes, obesity, and other metabolic diseases.